Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06332755 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
A Phase 1 study of Urothelial Carcinoma and Malignant Melanoma, sponsored by LG Chem.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT06332755 is a Phase 1 study of Urothelial Carcinoma and Malignant Melanoma that is actively recruiting participants, run by LG Chem. The registered enrollment target is 76 participants, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06332755, a Phase 1 study of Urothelial Carcinoma and Malignant Melanoma, is actively recruiting participants, sponsored by LG Chem.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109 as monotherapy in participants with advanced and/or metastatic non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options, and as combination therapy with atezolizumab in participants with advanced and/or metastatic NSCLC.
Conditions Studied
Interventions
- DRUG Phase 1a: LB-LR1109
- DRUG Phase 1b: LB-LR1109 and Atezolizumab
Study Locations (1)
Virginia
- NEXT Oncology - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2024-06-05 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06332755
The ClinicalTrials.gov registry entry for NCT06332755 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (68% lower). The listed sponsor is LG Chem, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Phase 1a: LB-LR1109 is the first listed.
NCT06332755 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06332755 about?
NCT06332755 is a clinical study titled "Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC". This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacody...
What is the current status of trial NCT06332755?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2024-06-05. Estimated completion is 2028-03.
What conditions does trial NCT06332755 study?
This clinical trial studies the following conditions: Urothelial Carcinoma, Malignant Melanoma, Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC).
What interventions are being tested in trial NCT06332755?
The interventions under investigation include: Phase 1a: LB-LR1109 (DRUG), Phase 1b: LB-LR1109 and Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT06332755?
This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06332755 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.